TABLE 5.
Skeletal muscle analysis before (pre) and 2 wk after (post) eTRF1
| Pre-eTRF | Post-eTRF | |||
|---|---|---|---|---|
| Characteristic | 0 min | 180 min | 0 min | 180 min |
| BCAA, µmol·kgDW−1 | 2059 ± 150 | 1839 ± 122 | 1934 ± 132 | 2015 ± 171 |
| KA, µmol·kgDW−1 | 56.4 ± 6.2 | 44.6 ± 8.3 | 58.0 ± 8.2 | 55.7 ± 12.0 |
| Glycogen, mmol glycosyl units·kgDW−1 | 359 ± 25 | 360 ± 36 | 382 ± 48 | 380 ± 43 |
| PDC activity, nmol·mg protein−1· min−1 | 4.17 ± 0.64 | 4.41 ± 0.61** | 3.77 ± 0.34 | 5.42 ± 0.74** |
1Data are means ± SEMs; n = 7. Mixed-design 2-factor ANOVA revealed no intervention or interaction effects for muscle BCAA (P = 0.89 and P = 0.10, respectively), KA (P = 0.53 and P = 0.37, respectively), glycogen (P = 0.57 and P = 0.96, respectively), or PDC (P = 0.69 and P = 0.30, respectively). A time effect (**P = 0.002 from respective 0 min) was observed for PDC only. BCAA, branched-chain amino acid (sum of leucine, isoleucine, and valine); DW, dry weight; eTRF, early time-restricted feeding; KA, branched-chain keto acids (sum of ketoisocaproic, 2-keto-3-methyl-valeric, and ketoisovaleric acids); PDC, pyruvate dehydrogenase complex.